No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer
- 18 October 2005
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 240 (2) , 195-197
- https://doi.org/10.1016/j.canlet.2005.09.003
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in HumansCell, 2004
- BRCA1 mutations in southern England.British Journal of Cancer, 1998
- Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.Genes & Development, 1997
- Abnormal expression of MDM-2 in breast carcinomasBreast Cancer Research and Treatment, 1996
- MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation statusBritish Journal of Cancer, 1995
- Genetic epidemiology of early onset breast cancer.Journal of Medical Genetics, 1994
- Amplification of a gene encoding a p53-associated protein in human sarcomasNature, 1992